Feedback Loop Drives Colorectal Cancer Through FAK/AKT

Why It Matters

Targeting the EIF4A3/circPTGR1/miR‑4725‑5p circuit could provide a novel RNA‑based strategy to inhibit FAK/AKT‑driven tumor growth and serve as a biomarker for aggressive colorectal cancer.

Key Takeaways

• EIF4A3 overexpressed in colorectal tumors
• circPTGR1 sponges miR‑4725‑5p, stabilizing its levels
• Positive feedback loop amplifies FAK/AKT signaling
• Disrupting loop reduces proliferation, induces apoptosis
• Biomarkers may guide patient stratification

Pulse Analysis

Colorectal cancer remains a leading cause of cancer mortality worldwide, and recent molecular studies have turned attention to the regulatory network of non‑coding RNAs. The new study identifies EIF4A3, a translation initiation factor, as markedly up‑regulated in tumor tissue, where it drives the production of circPTGR1, a circular RNA that acts as a sponge for miR‑4725‑5p. By sequestering this microRNA, circPTGR1 prevents its tumor‑suppressive activity, creating a permissive environment for oncogenic signaling. This triad—EIF4A3, circPTGR1, and miR‑4725‑5p—forms the core of a previously uncharacterized feedback circuit that fuels colorectal cancer progression.

The researchers demonstrated that elevated EIF4A3 levels boost circPTGR1 expression, which in turn stabilizes miR‑4725‑5p, establishing a positive‑feedback loop that intensifies FAK and AKT phosphorylation. Activation of the FAK/AKT axis promotes cell adhesion, migration, and survival, hallmarks of aggressive tumors. Experimental knockdown of any component of the loop resulted in diminished FAK/AKT activity, reduced proliferation, and increased apoptosis in colorectal cancer cell lines. These findings link the RNA‑based circuit directly to a well‑known oncogenic pathway, explaining how dysregulated non‑coding RNAs can drive metastatic potential.

The identification of the EIF4A3/circPTGR1/miR‑4725‑5p loop opens several translational avenues. Small‑molecule inhibitors or antisense oligonucleotides that disrupt EIF4A3 binding or circPTGR1 formation could blunt FAK/AKT signaling and restore miR‑4725‑5p tumor‑suppressor function. Moreover, quantifying these RNAs in patient biopsies may serve as prognostic biomarkers, enabling risk‑adapted therapy and monitoring of treatment response. While RNA‑based therapeutics face delivery challenges, advances in nanoparticle carriers and CRISPR‑Cas systems make clinical exploitation increasingly feasible. Continued validation in animal models will be essential before moving to early‑phase trials.